GLP-1s – Patient Worthy

source: pixabay.com

Eli Lilly Advances Oral GLP‑1 With Strong Phase 3 Data in Type 2 Diabetes

Post author:Austin Newman
Post published:June 12, 2026
Post category:Diabetes Type 2

As reported on BioSpace, Eli Lilly is moving closer to expanding the use of its oral GLP‑1 receptor agonist orforglipron, marketed as Foundayo, into type 2 diabetes (T2D), following encouraging…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More